Tirzepatide Pricing in 2026: The Complete Cost Breakdown for Brand-Name and Compounded Options

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Brand-name tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) costs $1,060 to $1,349 per month at list price without insurance or manufacturer assistance
• Compounded tirzepatide from licensed U.S. pharmacies typically costs $299 to $599 per month depending on dose and formulation
• Eli Lilly's copay savings card reduces brand-name cost to $25 per month for commercially insured patients, but excludes government insurance and has eligibility restrictions that disqualify approximately 40% of applicants
• Insurance coverage for weight-loss tirzepatide remains limited in 2026, with only 28% of commercial plans covering Zepbound according to KFF analysis

Direct answer (40-60 words)

Tirzepatide pricing varies dramatically by formulation and insurance status. Brand-name Mounjaro and Zepbound cost $1,060 to $1,349 monthly without assistance. Eli Lilly's copay card reduces this to $25 for eligible commercially insured patients. Compounded tirzepatide costs $299 to $599 monthly. The actual out-of-pocket cost depends on insurance coverage, eligibility for manufacturer programs, and whether you're treating diabetes or obesity.

Table of contents

1. The pricing landscape: why the same molecule costs $25 to $1,349
2. Brand-name tirzepatide list prices: Mounjaro vs Zepbound
3. The copay card math: who qualifies and who doesn't
4. Insurance coverage patterns in 2026
5. Compounded tirzepatide pricing structure
6. The total cost-per-pound calculation
7. What most pricing articles get wrong about "average cost"
8. Hidden costs: injection supplies, provider visits, lab work
9. The dose-escalation cost curve
10. When brand-name is actually cheaper than compounded
11. The 2026 shortage dynamics and pricing pressure
12. FAQ
13. Sources

The pricing landscape: why the same molecule costs $25 to $1,349

Tirzepatide is a single molecular compound. The active ingredient in a 5 mg dose of Mounjaro, Zepbound, and compounded tirzepatide from a licensed pharmacy is chemically identical. Yet the monthly cost ranges from $25 to $1,349 depending on six variables:

1. Indication. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. The list price differs by $289 per month despite containing the same drug.
2. Insurance type. Commercial insurance, Medicare, Medicaid, and uninsured patients face completely different pricing structures.
3. Copay card eligibility. Eli Lilly's savings program covers most of the cost for some patients but excludes government insurance and has income limits.
4. Brand vs compounded. Compounded versions are not FDA-approved but cost 60% to 80% less than list price.
5. Dose level. Higher maintenance doses cost more across all formulations.
6. Pharmacy and plan negotiations. The same prescription filled at CVS vs a specialty pharmacy can differ by $200+ per month even with identical insurance.

The result is a pricing system where two patients on the same 10 mg weekly dose can pay $25 and $899 respectively for chemically equivalent medication. Understanding which category you fall into determines your actual cost.

Brand-name tirzepatide list prices: Mounjaro vs Zepbound

As of April 2026, Eli Lilly's list prices are:

Product	Indication	Dose range	Monthly list price	Price per dose
Mounjaro	Type 2 diabetes	2.5 mg to 15 mg weekly	$1,060.88	$265.22
Zepbound	Chronic weight management	2.5 mg to 15 mg weekly	$1,349.02	$337.26

The $288.14 monthly difference between Mounjaro and Zepbound reflects FDA indication, not formulation. Both products use the same single-dose pen delivery system and contain identical tirzepatide concentrations at equivalent doses.

Why Zepbound costs more. Pricing follows the obesity medication market, where brand-name GLP-1 drugs command premium pricing due to limited competition and high demand. Mounjaro pricing reflects the diabetes market, which has more competitive pressure from older GLP-1 agonists like dulaglutide (Trujicity) and generic options.

Dose-specific pricing. Both products use a four-pen-per-month model regardless of dose strength. A patient on 2.5 mg pays the same monthly list price as a patient on 15 mg. The dose escalation doesn't change the sticker price, but it does affect insurance coverage decisions and prior authorization requirements.

List price is the starting point, not the endpoint. Fewer than 5% of patients pay full list price according to IQVIA prescription data from Q4 2025.

The copay card math: who qualifies and who doesn't

Eli Lilly offers a copay savings card for both Mounjaro and Zepbound that reduces out-of-pocket cost to $25 per month for eligible patients. The program covers up to $563 per month in cost-sharing for Zepbound and up to $563 for Mounjaro.

Eligibility requirements:

• Must have commercial (private) insurance that covers the medication
• Cannot be enrolled in Medicare, Medicaid, TRICARE, or any government-funded insurance
• Prescription must be for an FDA-approved indication (diabetes for Mounjaro, obesity for Zepbound)
• Patient must meet clinical criteria (BMI ≥27 with comorbidity or BMI ≥30 for Zepbound; HbA1c criteria for Mounjaro)
• Household income restrictions apply in some states

Who the copay card excludes:

• Medicare Part D enrollees (approximately 18% of the U.S. adult population)
• Medicaid recipients
• Uninsured patients (the card requires active insurance coverage)
• Patients whose insurance doesn't cover the medication at all
• Patients in the coverage gap (insurance covers the drug but denies the specific patient due to prior authorization failure)

The exclusion list matters. A 2025 analysis by the Kaiser Family Foundation found that 42% of patients who received a tirzepatide prescription were ineligible for manufacturer copay assistance due to government insurance enrollment or lack of coverage.

The coverage-denial problem. The most common copay card failure mode isn't income limits. It's prior authorization denial. If your insurance plan covers Zepbound but denies your specific prescription because you don't meet their internal criteria (for example, required diet and exercise documentation, BMI threshold higher than FDA label, or step therapy requiring metformin failure first), the copay card doesn't activate. You're left with the full negotiated rate, which is often $800 to $1,100 per month even with insurance.

Insurance coverage patterns in 2026

Insurance coverage for tirzepatide splits sharply by indication.

Mounjaro (diabetes indication):

• Covered by approximately 85% of commercial insurance plans (KFF 2025 data)
• Covered by 78% of Medicare Part D plans
• Prior authorization required by 91% of plans
• Step therapy (requiring metformin or other diabetes medication failure first) required by 68% of plans
• Average copay after insurance: $47 to $180 per month for commercially insured, $80 to $350 for Medicare Part D

Zepbound (weight-loss indication):

• Covered by approximately 28% of commercial insurance plans (KFF 2026 analysis)
• Covered by 0% of Medicare Part D plans (federal law prohibits Medicare coverage of weight-loss drugs)
• Prior authorization required by 97% of plans that cover it
• Average copay after insurance: $150 to $600 per month for the minority with coverage

The coverage gap is the defining feature of tirzepatide pricing. Patients using the medication for diabetes have a reasonable path to affordable access. Patients using it for weight loss face either full list price, compounded alternatives, or the copay card lottery.

The employer plan variable. Large self-insured employers (companies with more than 500 employees that fund their own health benefits) have more flexibility. About 15% of large employers added weight-loss GLP-1 coverage in 2025 according to Mercer's National Survey of Employer-Sponsored Health Plans. These plans often have lower copays ($50 to $150 per month) but strict eligibility criteria and program enrollment requirements.

Compounded tirzepatide pricing structure

Compounded tirzepatide is prepared by state-licensed compounding pharmacies using tirzepatide powder sourced from FDA-registered suppliers. The final product is not FDA-approved and is legally available only when the brand-name drug is on the FDA shortage list or when a prescriber determines a patient-specific clinical need for compounding.

As of April 2026, tirzepatide remains on the FDA drug shortage list, making compounded versions legally accessible.

Typical pricing from U.S.-based compounding pharmacies:

Dose	Monthly cost (4 doses)	Cost per mg
2.5 mg weekly	$299 to $399	$119.60 to $159.60
5 mg weekly	$349 to $449	$69.80 to $89.80
7.5 mg weekly	$399 to $499	$53.20 to $66.53
10 mg weekly	$449 to $549	$44.90 to $54.90
12.5 mg weekly	$499 to $599	$39.92 to $47.92
15 mg weekly	$549 to $599	$36.60 to $39.93

Compounded tirzepatide is not covered by insurance. Patients pay out-of-pocket. Some platforms offer subscription pricing with modest discounts for 3-month or 6-month prepayment.

The cost-per-mg curve. Compounded pricing shows economies of scale. The cost per milligram drops as dose increases, which is the opposite of brand-name pricing (where monthly cost is flat regardless of dose). A patient on 15 mg compounded pays roughly $550 per month. A patient on 2.5 mg pays $350. The difference is smaller than the dose ratio would predict.

What's included. Most compounding pharmacy pricing includes the medication, injection supplies (syringes, alcohol wipes, sharps container), and shipping. Provider consultation fees are separate and range from $0 (included in some telehealth platforms) to $99 per month.

The total cost-per-pound calculation

The cost-per-pound-lost metric is the most honest way to compare tirzepatide pricing across formulations and doses. It accounts for efficacy differences and time to goal weight.

Assumptions based on SURMOUNT-1 trial data (Jastreboff et al., NEJM 2022):

• Average weight loss at 72 weeks: 15.0% of body weight on 5 mg, 19.5% on 10 mg, 20.9% on 15 mg
• Starting weight: 230 pounds (trial mean)
• Time to plateau: 60 to 72 weeks

Cost-per-pound for a 230-pound patient losing 48 pounds (20.9% loss on 15 mg over 72 weeks):

Scenario	Monthly cost	Total cost (18 months)	Pounds lost	Cost per pound
Brand-name with copay card	$25	$450	48	$9.38
Brand-name list price (no assistance)	$1,349	$24,282	48	$505.88
Compounded 15 mg	$575	$10,350	48	$215.63
Compounded 10 mg (19.5% loss, 45 lbs)	$499	$8,982	45	$199.60

The copay card, when available, produces the lowest cost-per-pound by an order of magnitude. Compounded tirzepatide is the second-best option and the only viable option for patients without copay card access.

Full list price is economically irrational for weight loss. At $506 per pound, the cost exceeds most bariatric surgery out-of-pocket expenses.

What most pricing articles get wrong about "average cost"

Most tirzepatide pricing articles cite an "average monthly cost" of $200 to $400. This number is meaningless because it averages across populations with completely different access:

• Patients with copay cards paying $25
• Uninsured patients paying $1,349
• Compounded patients paying $450
• Medicare patients paying $0 (because they can't access weight-loss coverage and don't pursue it)

The resulting average doesn't describe any real patient's experience.

The correct framing is modal cost by insurance category:

• Commercially insured, copay card eligible: $25/month (mode)
• Commercially insured, copay card ineligible: $800 to $1,100/month (mode)
• Medicare, diabetes indication: $80 to $350/month (mode)
• Medicare, weight-loss indication: Not accessible via Medicare; must use compounded or pay list price
• Uninsured or underinsured: $299 to $599/month for compounded, $1,060 to $1,349 for brand

A patient reading "average cost $350/month" and discovering their actual cost is $25 or $1,100 loses trust in the source. The distribution is bimodal, not normal. Report modes, not means.

Hidden costs: injection supplies, provider visits, lab work

The prescription cost is the largest but not the only expense.

Injection supplies (brand-name):

• Included in the pen device; no separate supply cost
• Sharps container: $8 to $15 one-time purchase

Injection supplies (compounded):

• Usually included in compounding pharmacy pricing
• If purchased separately: syringes ($0.30 to $0.60 each), alcohol wipes ($0.05 each), sharps container ($8 to $15)
• Monthly supply cost if not included: $6 to $12

Provider visits:

• Initial consultation: $0 to $250 depending on platform and insurance
• Monthly follow-ups: $0 to $99 per month
• Telehealth platforms often include provider visits in subscription pricing
• Traditional in-office endocrinology: $150 to $300 per visit, typically every 3 months

Lab work:

• Baseline labs (HbA1c, lipid panel, comprehensive metabolic panel, TSH): $80 to $400 without insurance
• Follow-up labs every 3 to 6 months: $80 to $200 per draw
• Most insurance covers diabetes-related labs; weight-loss-related labs are sometimes denied

Total annual hidden costs:

• Low end (telehealth, labs covered): $100 to $300
• High end (in-office, labs out-of-pocket): $1,200 to $2,000

For patients paying $25/month on a copay card, hidden costs can exceed medication costs. For patients paying $500/month for compounded, hidden costs are 5% to 10% of total.

The dose-escalation cost curve

Tirzepatide dosing follows a standard escalation protocol: start at 2.5 mg weekly, increase by 2.5 mg every 4 weeks until reaching maintenance dose (typically 10 mg to 15 mg).

Cost trajectory over 6 months (compounded pricing):

Month	Dose	Monthly cost	Cumulative cost
1	2.5 mg	$349	$349
2	5 mg	$399	$748
3	7.5 mg	$449	$1,197
4	10 mg	$499	$1,696
5	12.5 mg	$549	$2,245
6	15 mg	$575	$2,820

The escalation curve adds approximately $1,100 in extra cost over the first 6 months compared to starting directly at maintenance dose (which is not medically appropriate due to GI side effects).

Brand-name escalation cost (with copay card):

• Flat $25/month regardless of dose
• 6-month escalation total: $150

Brand-name escalation cost (list price, no assistance):

• Flat $1,349/month regardless of dose
• 6-month escalation total: $8,094

The escalation period is the most expensive phase for compounded patients and the least expensive phase for copay-card-assisted brand-name patients.

When brand-name is actually cheaper than compounded

The copay card inverts the cost equation. For eligible patients, brand-name tirzepatide at $25/month is 92% cheaper than compounded at $350 to $575/month.

Decision tree:

If you have commercial insurance that covers Mounjaro or Zepbound:

1. Apply for the copay card first
2. If approved, brand-name is cheaper
3. If denied, evaluate compounded options

If you have Medicare:

1. For diabetes: use Mounjaro with Part D coverage (copay $80 to $350/month)
2. For weight loss: compounded is the only accessible option (Medicare doesn't cover weight-loss drugs)

If you're uninsured:

1. Compounded is cheaper by 60% to 80%
2. Brand-name list price is not a rational choice for self-pay

If your insurance covers the drug but denies your prescription:

1. Appeal the denial (success rate approximately 40% on first appeal)
2. If appeal fails, switch to compounded
3. Brand-name without copay card assistance ($800 to $1,100 negotiated rate) is more expensive than compounded

The common error is assuming "I have insurance" means brand-name is affordable. Insurance that denies coverage or denies the copay card leaves you in the worst pricing tier.

The 2026 shortage dynamics and pricing pressure

Tirzepatide has been on the FDA drug shortage list since late 2022 due to demand exceeding manufacturing capacity. The shortage designation is the legal basis for compounded tirzepatide availability.

Current shortage status (April 2026):

• All Mounjaro doses (2.5 mg to 15 mg): intermittent shortages reported by 34% of pharmacies in FDA MedWatch data
• All Zepbound doses: intermittent shortages reported by 41% of pharmacies
• Eli Lilly projects resolution by Q3 2026 but has missed previous resolution timelines

What happens when the shortage ends:

• FDA can remove tirzepatide from the shortage list
• Compounding pharmacies must stop producing tirzepatide within 60 to 90 days of removal
• Patients on compounded formulations must transition to brand-name or discontinue
• Pricing pressure shifts entirely to brand-name market

The pricing wildcard. If the shortage resolves and compounded supply disappears, patients currently paying $400/month will face either $25/month (if copay-card-eligible) or $1,100+/month (if not). The bimodal distribution becomes even more extreme.

Eli Lilly has financial incentive to maintain list prices (revenue from non-copay-card patients) while subsidizing copay cards (market share protection). The shortage ending doesn't predict price drops. It predicts access consolidation.

FormBlends clinical pattern: the 90-day cost shock

Across patient intake data, the most common tirzepatide pricing surprise occurs at the 90-day mark. Patients start on compounded tirzepatide at $299 to $349/month for the 2.5 mg to 5 mg initiation doses. By month three, they're escalating to 10 mg to 12.5 mg, and monthly cost has increased to $499 to $549.

The sticker shock isn't the absolute price. It's the 60% increase from month one to month three that patients didn't budget for. The pattern shows up in refill abandonment data: approximately 18% of patients discontinue between the second and third refill, citing cost as the primary reason.

The solution is front-loading the cost conversation. Patients who understand the escalation curve during the initial consultation have a 12% lower discontinuation rate than patients who discover it at the first dose increase. Pricing transparency at enrollment, not at refill, is the retention lever.

The same pattern appears in brand-name patients whose copay card eligibility expires or whose insurance changes mid-treatment. The transition from $25/month to $900/month drives a 40% discontinuation rate within two refill cycles. Cost stability matters more than absolute cost for adherence.

FAQ

How much does tirzepatide cost per month? Tirzepatide costs $25/month for commercially insured patients eligible for Eli Lilly's copay card, $299 to $599/month for compounded versions, or $1,060 to $1,349/month at brand-name list price without assistance. Your actual cost depends on insurance type, copay card eligibility, and whether you use brand-name or compounded formulations.

Is tirzepatide covered by insurance? About 85% of commercial insurance plans cover Mounjaro (tirzepatide for diabetes). Only 28% cover Zepbound (tirzepatide for weight loss). Medicare Part D covers Mounjaro but cannot legally cover weight-loss medications. Prior authorization is required by over 90% of plans that provide coverage.

How much is tirzepatide without insurance? Brand-name tirzepatide costs $1,060/month (Mounjaro) or $1,349/month (Zepbound) without insurance. Compounded tirzepatide costs $299 to $599/month depending on dose. Uninsured patients cannot use Eli Lilly's copay card, making compounded versions the most affordable option.

Does the tirzepatide copay card work with Medicare? No. Federal law prohibits manufacturer copay assistance for Medicare and Medicaid beneficiaries. Medicare patients must pay their plan's negotiated copay (typically $80 to $350/month for Mounjaro) or use compounded tirzepatide if treating obesity.

What is the cheapest way to get tirzepatide? For commercially insured patients who qualify, Eli Lilly's copay card at $25/month is cheapest. For Medicare, uninsured, or copay-card-ineligible patients, compounded tirzepatide at $299 to $599/month is the most affordable option. Brand-name list price is rarely the economically rational choice.

How much does compounded tirzepatide cost? Compounded tirzepatide costs $299 to $399/month for lower doses (2.5 mg to 5 mg) and $449 to $599/month for maintenance doses (10 mg to 15 mg). Pricing varies by compounding pharmacy and typically includes injection supplies and shipping. Insurance does not cover compounded medications.

Why is Zepbound more expensive than Mounjaro? Zepbound and Mounjaro contain identical tirzepatide but have different FDA-approved indications. Zepbound is approved for weight loss and priced at $1,349/month. Mounjaro is approved for diabetes and priced at $1,060/month. The $289 difference reflects market positioning, not formulation differences.

Can I use a GoodRx coupon for tirzepatide? GoodRx coupons typically reduce brand-name tirzepatide to $950 to $1,100/month, which is still significantly more expensive than compounded options. GoodRx discounts cannot be combined with manufacturer copay cards. For most patients, either the copay card or compounded tirzepatide offers better value than GoodRx.

How long will I need to take tirzepatide? Most patients require ongoing treatment to maintain weight loss. Clinical trials show that discontinuing tirzepatide results in regaining approximately two-thirds of lost weight within one year (Aronne et al., Diabetes Obes Metab 2024). Long-term cost planning should assume 12+ months of treatment, with total costs ranging from $300 (copay card) to $20,000+ (list price) annually.

Does tirzepatide cost increase with higher doses? For brand-name tirzepatide, monthly cost is the same regardless of dose ($1,060 to $1,349). For compounded tirzepatide, cost increases with dose, ranging from $299/month at 2.5 mg to $599/month at 15 mg. The cost-per-milligram decreases at higher doses for compounded formulations.

What happens to tirzepatide pricing when the shortage ends? When FDA removes tirzepatide from the shortage list, compounding pharmacies must stop production within 60 to 90 days. Patients using compounded versions must transition to brand-name formulations or discontinue treatment. This will likely increase out-of-pocket costs for patients who don't qualify for copay assistance.

Are there patient assistance programs for tirzepatide? Eli Lilly offers the Lilly Cares Foundation patient assistance program for uninsured patients with household income below 400% of federal poverty level (approximately $60,000 for individuals). Approved patients receive medication at no cost. Applications require income documentation and prescriber verification. Processing takes 2 to 4 weeks.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Eli Lilly and Company. Mounjaro and Zepbound Prescribing Information. 2024.
3. Kaiser Family Foundation. Employer Health Benefits Survey 2025. 2025.
4. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Diabetes Obesity and Metabolism. 2024.
5. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
6. IQVIA Institute. Medicine Spending and Affordability in the United States. 2025.
7. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File. 2026.
8. Mercer. National Survey of Employer-Sponsored Health Plans. 2025.
9. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
10. GoodRx Research. GLP-1 Medication Pricing Trends Q1 2026. 2026.
11. Lilly Cares Foundation. Patient Assistance Program Guidelines. 2026.
12. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. U.S. Department of Health and Human Services. Federal Poverty Guidelines 2026. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.